Unnatural Products Inc. Secures $45 Million in Series B Funding
Unnatural Products Inc., a biotechnology company based in Santa Cruz, California, announced on March 16, 2026, the successful closure of a $45 million Series B funding round. The company is known for its development of macrocyclic peptide therapeutics, which aim to tackle previously undruggable targets. This funding round was led by The Venture Collective, with participation from key investors including Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, and Droia Ventures.
Company Leadership and Vision
Cameron Pye, the CEO of Unnatural Products Inc., expressed confidence in the company's innovative platform. "Macrocyclic peptides represent a powerful new therapeutic modality," Pye stated. He highlighted that their platform combines the precision of biologics with the delivery advantages of small molecules, enabling the targeting of complex intracellular pathways that have been historically challenging to address.
Strategic Use of Funds
The newly acquired funds will be directed towards enhancing the company’s proprietary drug discovery platform. This will support the advancement of its pipeline of macrocyclic peptide therapeutics. These peptides are designed to target complex biological pathways, offering solutions where traditional methods have fallen short.
Investor Contributions
The Series B round's lead investor, The Venture Collective, along with other prominent investors like Merck Global Health Innovation Fund and Artis Ventures, shows strong support for Unnatural Products Inc.'s approach to drug development. The involvement of these investors underscores a growing interest in biotech platforms that address unmet medical needs.
Industry Context
Unnatural Products Inc. is part of a broader trend in the biotech industry that focuses on developing novel therapeutic modalities. The company's recent licensing agreement with Novartis to develop macrocyclic peptide therapeutics for cardiovascular targets is a testament to its potential impact in the field. This agreement includes up to $100 million upfront and up to $1.7 billion in total potential milestones, further highlighting the significance of their research and development efforts.
This funding round marks a significant milestone for Unnatural Products Inc., positioning the company to make substantial advances in the field of peptide therapeutics. With strong backing from leading investors, the company is well-placed to continue its mission of targeting previously undruggable diseases.